| EBITDA Margin guidance | 26.0% → 26.8% Raised by 0.8 percentage points |
|---|---|
| Management target | Revenue 100.0% FY30 |
| Revenue growth | Consolidated Q2 +31% YoY; H1 organic +14%, acquisitions drive rest. |
|---|---|
| Margins | Gross margin 70.1% in Q2, down from 73.4% QoQ; Pendra Care loss-making. |
| Demand visibility | Europe Q2 organic ~40%; RoW down 7% on freight and West Asia. |
| Management confidence | Optimistic; reaffirms revenue guidance, raises standalone margin band. |
Growth
Consolidated Q2 revenue ₹581 Cr (+31% YoY), with acquisitions driving most of the gap versus 14% H1 organic growth.
Outlook
FY27 consolidated revenue ₹2,300–2,400 Cr reaffirmed; standalone EBITDA margin band raised to 26–27.5%.
Risks
Pendra Care is loss-making on Middle East exposure, Italy tender delays persist, and Chinese dialysis dumping remains unresolved.
Last quarter's promises, checked
Delivered
- Standalone EBITDA 25–27% → Q1 28%, band raised to 26–27.5% (= BEAT)
- Europe organic 17–18% → Q2 ~40% (= BEAT)
Partly delivered
- Consolidated revenue ₹2,300–2,400 Cr → Q1 ₹525 Cr, Q2 ₹581 Cr, reaffirmed (= PARTIAL)
- Capex ₹200–225 Cr → H1 ₹124 Cr (= PARTIAL)
- Consolidated EBITDA 23–25% → Q1 24%, Q2 not disclosed (= PARTIAL)
Missed
- Consolidated gross margin 71–72% → Q2 70.1% (= MISS)
- Middle East 20–25%+ growth once West Asia normalises → RoW down 7% (= MISS)
Earnings Call Transcript filed with NSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,615.00
- Market cap
- ₹16,370 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 52.0×Sector 54.5×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Other Announcement
Poly Medicure's board revised five governance policies and codes, including material subsidiary, materiality, related party transactions, and insider trading codes. The revised documents are published on the company website.
Poly Medicure Q2 FY27 Results: Net Profit ₹95.1 Cr, Up 3.6% YoY
Poly Medicure Ltd reported revenue from operations of ₹580.5 Cr (+30.8% YoY) and net profit of ₹95.1 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹95.1 Cr · +3.6% YoY
Poly Medicure Board Meeting Date
Poly Medicure will hold a board meeting on 05 November 2026 to consider unaudited results. Trading window stays closed until 07 November 2026.
Poly Medicure Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Annual Report
Poly Medicure has filed its Notice of the 31st Annual General Meeting and the Annual Report for the financial year ended March 31, 2026.